Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Review

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(3):326-344. Published online April 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0155

View: 983 Download: 93

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 1981 Download: 60 Web of Science: 1 Crossref: 1

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 2142 Download: 94 Web of Science: 1 Crossref: 1

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 2720 Download: 60 Web of Science: 2 Crossref: 2

Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan

San-Chi Chen

Clin Mol Hepatol. 2023;29(2):352-354. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0101

View: 2742 Download: 64

Review

Detect or not to detect very early stage hepatocellular carcinoma? The western perspective

Ju Dong Yang

Clin Mol Hepatol. 2019;25(4):335-343. Published online March 29, 2019

DOI: https://doi.org/10.3350/cmh.2019.0010

View: 11117 Download: 246 Web of Science: 41 Crossref: 41

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2019;25(2):168-171. Published online February 11, 2019

DOI: https://doi.org/10.3350/cmh.2018.1014

View: 6029 Download: 180 Web of Science: 4 Crossref: 5

4

A Case of Complete Remission in Ruptured Hepatocellular Carcinoma after One - time Transcatheter Arterial Chemoembolization

Doo Yul Ryu,Duc Ky Lee,Jong Hyung Kim,Hyun Min Shin,Dong In Hwang,Dong Joo Lee,Sang Kook Han,Seok En Kim,Suk Joon Park

Clin Mol Hepatol. 1999;5(4):343-347. Published online January 1, 2000

PDF

View: 2252 Download: 13

3

Serum Concentration of Intercellular Adhesion Molecule-1 (ICAM-1) in Patients with Hepatocellular Carcinoma (HCC) with Low AFP

Hyun Ju Park, Joung Il Lee, Seok Ho Dong, Hyo Jong Kim, Byoung Ho Kim, Young Woon Chang and Rin Chang

Clin Mol Hepatol. 1998;4(4):346-357. Published online January 1, 2000

PDF

View: 2358 Download: 14

Original Article

Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Received January 20, 2024 Accepted May 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058 [Accepted]

PDF

View: 553 Download: 92

1 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

09 Days

Publication after acceptance

03 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 5662	MAFLD: How is it different from NAFLD?
Viewed By 5579	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5386	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5336	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4988	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 119	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 91	MAFLD: How is it different from NAFLD?
Cited By 82	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1145

TOTAL : 1947470